FDA May Ease Up On CV Safety Requirements For GI Motility Drugs Compared To Diabetes, Obesity
Executive Summary
Developers of 5-HT4 agonists should not be required to conduct dedicated cardiovascular studies, despite the safety concerns raised by two previously approved products in the class, an FDA advisory committee said.
You may also be interested in...
Shire’s Prucalopride Brings Real-World CV Safety Data To US FDA Panel, But Will It Be Enough?
European postmarketing epidemiological study results ‘reasonably exclude’ a greater than three-fold increased risk of major adverse cardiovascular events with the constipation drug but, due to potential bias, cannot definitively exclude a possibly unacceptable level of risk, agency says.
Keeping Track: FDA Approves Novel HIV Treatment, New Dosing Regimen For Opdivo; Another Rare Pediatric Disease Designation For Prometic
The latest drug development news and highlights from our US FDA Performance Tracker.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.